|Mr. Kevin C. Tang||Chairman & CEO||1||N/A||1967|
|Mr. John G. Lemkey||Chief Operating Officer||271.92k||N/A||1981|
|Dr. Joseph P. O'Connell M.D.||Chief Medical Officer||501.93k||N/A||1954|
|Mr. Michael S. Hearne||CFO & Principal Accounting Officer||N/A||N/A||1963|
|Dr. Steven S. Pfeiffer Ph.D.||VP of Technical Operations||N/A||N/A||1976|
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Odonate Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 1; Compensation: 6.